25 XP   0   0   10

Aprea Therapeutics Inc
Buy, Hold or Sell?

Let's analyse Aprea together

PenkeI guess you are interested in Aprea Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Aprea Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Aprea Therapeutics Inc

I send you an email if I find something interesting about Aprea Therapeutics Inc.

Quick analysis of Aprea (30 sec.)










What can you expect buying and holding a share of Aprea? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$5.43
Expected worth in 1 year
$3.73
How sure are you?
23.8%

+ What do you gain per year?

Total Gains per Share
$-1.70
Return On Investment
-27.9%

For what price can you sell your share?

Current Price per Share
$6.07
Expected price per share
$4.8201 - $9.04
How sure are you?
50%

1. Valuation of Aprea (5 min.)




Live pricePrice per Share (EOD)

$6.07

Intrinsic Value Per Share

$56.71 - $71.64

Total Value Per Share

$62.14 - $77.07

2. Growth of Aprea (5 min.)




Is Aprea growing?

Current yearPrevious yearGrowGrow %
How rich?$20.2m$20.9m$2.9m12.4%

How much money is Aprea making?

Current yearPrevious yearGrowGrow %
Making money-$30.3m-$29.5m-$803.8k-2.6%
Net Profit Margin-577.1%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Aprea (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#600 / 1031

Most Revenue
#612 / 1031

Most Profit
#833 / 1031

Most Efficient
#772 / 1031

What can you expect buying and holding a share of Aprea? (5 min.)

Welcome investor! Aprea's management wants to use your money to grow the business. In return you get a share of Aprea.

What can you expect buying and holding a share of Aprea?

First you should know what it really means to hold a share of Aprea. And how you can make/lose money.

Speculation

The Price per Share of Aprea is $6.07. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Aprea.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Aprea, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $5.43. Based on the TTM, the Book Value Change Per Share is $-0.42 per quarter. Based on the YOY, the Book Value Change Per Share is $-1.79 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Aprea.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.86-14.1%-0.81-13.4%-7.89-130.0%-3.29-54.2%-3.17-52.3%
Usd Book Value Change Per Share-0.84-13.8%-0.42-7.0%-1.79-29.5%-0.55-9.0%0.264.3%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.84-13.8%-0.42-7.0%-1.79-29.5%-0.55-9.0%0.264.3%
Usd Price Per Share4.17-3.02-1.53-9.09-8.65-
Price to Earnings Ratio-1.21--0.88--0.18--0.84--0.80-
Price-to-Total Gains Ratio-4.97-2.43--0.98--2.06--2.06-
Price to Book Ratio0.77-0.49-0.10-0.42-0.40-
Price-to-Total Gains Ratio-4.97-2.43--0.98--2.06--2.06-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share6.07
Number of shares164
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.42-0.55
Usd Total Gains Per Share-0.42-0.55
Gains per Quarter (164 shares)-69.52-89.68
Gains per Year (164 shares)-278.08-358.71
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-278-2880-359-369
20-556-5660-717-728
30-834-8440-1076-1087
40-1112-11220-1435-1446
50-1390-14000-1794-1805
60-1668-16780-2152-2164
70-1947-19560-2511-2523
80-2225-22340-2870-2882
90-2503-25120-3228-3241
100-2781-27900-3587-3600

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.021.00.00.0%0.021.00.00.0%
Book Value Change Per Share1.03.00.025.0%2.010.00.016.7%4.015.01.020.0%5.015.01.023.8%5.015.01.023.8%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.021.00.0%0.00.021.00.0%
Total Gains per Share1.03.00.025.0%2.010.00.016.7%4.015.01.020.0%5.015.01.023.8%5.015.01.023.8%

Fundamentals of Aprea

About Aprea Therapeutics Inc

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors, ovarian, breast, and prostate cancers. The company is also developing ATRN-1051, ATRN-354, and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.

Fundamental data was last updated by Penke on 2024-03-20 10:04:06.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Aprea Therapeutics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Aprea earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Aprea to the Biotechnology industry mean.
  • A Net Profit Margin of -1,003.1% means that $-10.03 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Aprea Therapeutics Inc:

  • The MRQ is -1,003.1%. The company is making a huge loss. -2
  • The TTM is -577.1%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-1,003.1%TTM-577.1%-426.0%
TTM-577.1%YOY--577.1%
TTM-577.1%5Y-115.4%-461.7%
5Y-115.4%10Y-109.9%-5.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1,003.1%-171.8%-831.3%
TTM-577.1%-205.8%-371.3%
YOY--262.1%+262.1%
5Y-115.4%-455.6%+340.2%
10Y-109.9%-589.0%+479.1%
1.1.2. Return on Assets

Shows how efficient Aprea is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Aprea to the Biotechnology industry mean.
  • -12.4% Return on Assets means that Aprea generated $-0.12 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Aprea Therapeutics Inc:

  • The MRQ is -12.4%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -101.0%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-12.4%TTM-101.0%+88.6%
TTM-101.0%YOY-70.9%-30.2%
TTM-101.0%5Y-41.1%-60.0%
5Y-41.1%10Y-39.3%-1.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-12.4%-12.5%+0.1%
TTM-101.0%-12.2%-88.8%
YOY-70.9%-11.2%-59.7%
5Y-41.1%-13.4%-27.7%
10Y-39.3%-14.7%-24.6%
1.1.3. Return on Equity

Shows how efficient Aprea is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Aprea to the Biotechnology industry mean.
  • -15.8% Return on Equity means Aprea generated $-0.16 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Aprea Therapeutics Inc:

  • The MRQ is -15.8%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -119.3%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-15.8%TTM-119.3%+103.6%
TTM-119.3%YOY-12.4%-107.0%
TTM-119.3%5Y-32.7%-86.7%
5Y-32.7%10Y-31.1%-1.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-15.8%-15.8%+0.0%
TTM-119.3%-15.7%-103.6%
YOY-12.4%-13.9%+1.5%
5Y-32.7%-18.3%-14.4%
10Y-31.1%-19.2%-11.9%

1.2. Operating Efficiency of Aprea Therapeutics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Aprea is operating .

  • Measures how much profit Aprea makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Aprea to the Biotechnology industry mean.
  • An Operating Margin of -1,101.8% means the company generated $-11.02  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Aprea Therapeutics Inc:

  • The MRQ is -1,101.8%. The company is operating very inefficient. -2
  • The TTM is -646.7%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-1,101.8%TTM-646.7%-455.1%
TTM-646.7%YOY--646.7%
TTM-646.7%5Y-129.3%-517.4%
5Y-129.3%10Y-123.2%-6.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1,101.8%-299.1%-802.7%
TTM-646.7%-210.1%-436.6%
YOY--279.7%+279.7%
5Y-129.3%-459.9%+330.6%
10Y-123.2%-596.9%+473.7%
1.2.2. Operating Ratio

Measures how efficient Aprea is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 11.03 means that the operating costs are $11.03 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Aprea Therapeutics Inc:

  • The MRQ is 11.027. The company is inefficient in keeping operating costs low. -1
  • The TTM is 6.413. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ11.027TTM6.413+4.614
TTM6.413YOY-+6.413
TTM6.4135Y1.283+5.130
5Y1.28310Y1.222+0.061
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ11.0272.861+8.166
TTM6.4133.193+3.220
YOY-3.615-3.615
5Y1.2835.560-4.277
10Y1.2227.396-6.174

1.3. Liquidity of Aprea Therapeutics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Aprea is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 6.15 means the company has $6.15 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Aprea Therapeutics Inc:

  • The MRQ is 6.154. The company is very able to pay all its short-term debts. +2
  • The TTM is 7.599. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ6.154TTM7.599-1.445
TTM7.599YOY7.205+0.395
TTM7.5995Y8.402-0.803
5Y8.40210Y8.648-0.245
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.1543.986+2.168
TTM7.5994.440+3.159
YOY7.2055.552+1.653
5Y8.4026.158+2.244
10Y8.6486.492+2.156
1.3.2. Quick Ratio

Measures if Aprea is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Aprea to the Biotechnology industry mean.
  • A Quick Ratio of 6.09 means the company can pay off $6.09 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Aprea Therapeutics Inc:

  • The MRQ is 6.086. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 7.355. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ6.086TTM7.355-1.269
TTM7.355YOY6.928+0.427
TTM7.3555Y7.652-0.297
5Y7.65210Y7.287+0.364
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.0863.638+2.448
TTM7.3554.168+3.187
YOY6.9285.515+1.413
5Y7.6526.012+1.640
10Y7.2876.209+1.078

1.4. Solvency of Aprea Therapeutics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Aprea assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Aprea to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.21 means that Aprea assets are financed with 21.3% credit (debt) and the remaining percentage (100% - 21.3%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Aprea Therapeutics Inc:

  • The MRQ is 0.213. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.180. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.213TTM0.180+0.033
TTM0.180YOY0.588-0.408
TTM0.1805Y0.415-0.235
5Y0.41510Y0.399+0.016
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2130.335-0.122
TTM0.1800.330-0.150
YOY0.5880.267+0.321
5Y0.4150.367+0.048
10Y0.3990.378+0.021
1.4.2. Debt to Equity Ratio

Measures if Aprea is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Aprea to the Biotechnology industry mean.
  • A Debt to Equity ratio of 27.0% means that company has $0.27 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Aprea Therapeutics Inc:

  • The MRQ is 0.270. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.220. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.270TTM0.220+0.050
TTM0.220YOY0.141+0.079
TTM0.2205Y0.137+0.083
5Y0.13710Y0.130+0.007
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2700.376-0.106
TTM0.2200.398-0.178
YOY0.1410.334-0.193
5Y0.1370.429-0.292
10Y0.1300.476-0.346

2. Market Valuation of Aprea Therapeutics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Aprea generates.

  • Above 15 is considered overpriced but always compare Aprea to the Biotechnology industry mean.
  • A PE ratio of -1.21 means the investor is paying $-1.21 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Aprea Therapeutics Inc:

  • The EOD is -1.770. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.215. Based on the earnings, the company is expensive. -2
  • The TTM is -0.879. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.770MRQ-1.215-0.555
MRQ-1.215TTM-0.879-0.335
TTM-0.879YOY-0.181-0.699
TTM-0.8795Y-0.838-0.042
5Y-0.83810Y-0.798-0.040
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.770-2.643+0.873
MRQ-1.215-2.418+1.203
TTM-0.879-2.742+1.863
YOY-0.181-4.123+3.942
5Y-0.838-6.257+5.419
10Y-0.798-6.478+5.680
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Aprea Therapeutics Inc:

  • The EOD is -2.438. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.673. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -1.014. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.438MRQ-1.673-0.764
MRQ-1.673TTM-1.014-0.659
TTM-1.014YOY-0.188-0.827
TTM-1.0145Y-1.042+0.028
5Y-1.04210Y-0.992-0.050
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.438-3.244+0.806
MRQ-1.673-2.939+1.266
TTM-1.014-3.478+2.464
YOY-0.188-5.592+5.404
5Y-1.042-8.473+7.431
10Y-0.992-8.881+7.889
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Aprea is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.77 means the investor is paying $0.77 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Aprea Therapeutics Inc:

  • The EOD is 1.118. Based on the equity, the company is underpriced. +1
  • The MRQ is 0.767. Based on the equity, the company is cheap. +2
  • The TTM is 0.486. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD1.118MRQ0.767+0.351
MRQ0.767TTM0.486+0.281
TTM0.486YOY0.097+0.389
TTM0.4865Y0.424+0.062
5Y0.42410Y0.404+0.020
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.1182.124-1.006
MRQ0.7672.041-1.274
TTM0.4862.118-1.632
YOY0.0972.915-2.818
5Y0.4243.682-3.258
10Y0.4044.114-3.710
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Aprea Therapeutics Inc.

3.1. Institutions holding Aprea Therapeutics Inc

Institutions are holding 17.655% of the shares of Aprea Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31AIGH Capital Management, LLC9.34790.649534930000
2023-12-31Sio Capital Management, LLC7.49330.299628000000
2023-12-31Worth Venture Partners, LLC2.33280.22148716900
2023-12-31Walleye Trading Advisors, LLC2.14090.000880000-2356-2.8608
2023-12-31Royal Bank of Canada1.17820.0001440254370813788.0126
2023-12-31Vanguard Group Inc0.9283034688734726.8717
2023-12-31Geode Capital Management, LLC0.467601747300
2023-12-31Morgan Stanley - Brokerage Accounts0.4608017218265618.2393
2023-12-31BlackRock Inc0.227608504-726-7.8657
2023-12-31Bank of America Corp0.0870325110.0308
2023-12-31Group One Trading, LP0.05780216000
2023-09-30PNC Financial Services Group Inc0.02680100000
2023-12-31Tower Research Capital LLC0.01470548-1199-68.6319
2023-12-31Wells Fargo & Co0.0073027220.7407
2023-12-31Advisor Group Holdings, Inc.0.0054020000
2023-12-31JPMorgan Chase & Co0.000105125
2023-12-31UBS Group AG0.00010300
2023-12-31Creative Planning Inc000-25-100
2023-09-30Northwestern Mutual Wealth Management Co000-47-100
2023-12-31Bull Oak Capital, LLC000-39-100
Total 24.77661.1714925816+49323+5.3%

3.2. Funds holding Aprea Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Vanguard Total Stock Mkt Idx Inv2.30908628050501141.147
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr0.76440.00022856200
2024-01-31Fidelity Extended Market Index0.40260.00021504400
2024-01-31DFA US Core Equity 1 I0.05860219000
2023-12-31NT Ext Equity Mkt Idx Fd - L0.05490.0002205300
2023-12-31Northern Trust Extended Eq Market Idx0.05490.0002205300
2024-01-31Fidelity Series Total Market Index0.04680174864858.9091
2023-09-30BlackRock Extended Mkt Composite0.03560133100
2023-12-31BlackRock Extended Equity Market K0.031101161-2-0.172
2024-02-29Vanguard Instl Ttl Stk Mkt Idx InstlPls0.03040113600
2023-10-31Vanguard Instl Ttl Stck Mkt Idx Tr0.030401136-3854-77.2345
2024-02-29LUX IM Global Medtech HX0.02350.00387700
2024-01-31Fidelity Total Market Index0.0223083300
2023-12-31NT Ext Equity Mkt Idx Fd - NL0.0137051100
2023-12-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.011041010.2445
2024-02-29Dimensional US Core Equity 2 ETF0.0109040900
2023-12-31SSgA U.S. Extended Market Index Class I0.0090.000133500
2024-02-29State St US Extended Mkt Indx NL Cl C0.0090.000133500
2024-01-31Spartan Extended Market Index Pool E0.00730.000127400
2024-01-31Spartan Total Market Index Pool E0.0055020400
Total 3.93090.0041146882+47294+32.2%

3.3. Insider Transactions

Insiders are holding 11.5% of the shares of Aprea Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-03-13Bernd R SeizingerBUY68607.29
2024-03-13John P HamillBUY10107.29
2024-03-13Oren GiladBUY20007.29
2023-06-06Bernd R SeizingerBUY40683.63

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Aprea Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.838-0.424-49%-1.792+114%-0.547-35%0.259-424%
Book Value Per Share--5.4306.412-15%5.616-3%11.479-53%11.712-54%
Current Ratio--6.1547.599-19%7.205-15%8.402-27%8.648-29%
Debt To Asset Ratio--0.2130.180+18%0.588-64%0.415-49%0.399-47%
Debt To Equity Ratio--0.2700.220+23%0.141+91%0.137+97%0.130+107%
Dividend Per Share----0%-0%-0%-0%
Eps---0.858-0.814-5%-7.893+820%-3.291+284%-3.174+270%
Free Cash Flow Per Share---0.622-0.839+35%-2.085+235%-1.922+209%-1.871+201%
Free Cash Flow To Equity Per Share---0.646-0.496-23%-1.857+188%0.188-444%0.174-470%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--71.640--------
Intrinsic Value_10Y_min--56.706--------
Intrinsic Value_1Y_max---5.410--------
Intrinsic Value_1Y_min---5.322--------
Intrinsic Value_3Y_max---6.661--------
Intrinsic Value_3Y_min---6.553--------
Intrinsic Value_5Y_max--3.655--------
Intrinsic Value_5Y_min--2.566--------
Market Cap22681586.900+31%15568835.55511291749.656+38%5726446.775+172%33950916.536-54%32334206.225-52%
Net Profit Margin---10.031-5.771-42%--100%-1.154-88%-1.099-89%
Operating Margin---11.018-6.467-41%--100%-1.293-88%-1.232-89%
Operating Ratio--11.0276.413+72%-+100%1.283+760%1.222+803%
Pb Ratio1.118+31%0.7670.486+58%0.097+689%0.424+81%0.404+90%
Pe Ratio-1.770-46%-1.215-0.879-28%-0.181-85%-0.838-31%-0.798-34%
Price Per Share6.070+31%4.1673.022+38%1.533+172%9.086-54%8.653-52%
Price To Free Cash Flow Ratio-2.438-46%-1.673-1.014-39%-0.188-89%-1.042-38%-0.992-41%
Price To Total Gains Ratio-7.248-46%-4.9752.428-305%-0.979-80%-2.059-59%-2.059-59%
Quick Ratio--6.0867.355-17%6.928-12%7.652-20%7.287-16%
Return On Assets---0.124-1.010+712%-0.709+470%-0.411+230%-0.393+216%
Return On Equity---0.158-1.193+656%-0.124-22%-0.327+107%-0.311+97%
Total Gains Per Share---0.838-0.424-49%-1.792+114%-0.547-35%0.259-424%
Usd Book Value--20289298.00023958434.500-15%20985797.250-3%42893355.850-53%43762935.524-54%
Usd Book Value Change Per Share---0.838-0.424-49%-1.792+114%-0.547-35%0.259-424%
Usd Book Value Per Share--5.4306.412-15%5.616-3%11.479-53%11.712-54%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.858-0.814-5%-7.893+820%-3.291+284%-3.174+270%
Usd Free Cash Flow---2326044.000-3135635.250+35%-7792352.750+235%-7181889.900+209%-6989985.762+201%
Usd Free Cash Flow Per Share---0.622-0.839+35%-2.085+235%-1.922+209%-1.871+201%
Usd Free Cash Flow To Equity Per Share---0.646-0.496-23%-1.857+188%0.188-444%0.174-470%
Usd Market Cap22681586.900+31%15568835.55511291749.656+38%5726446.775+172%33950916.536-54%32334206.225-52%
Usd Price Per Share6.070+31%4.1673.022+38%1.533+172%9.086-54%8.653-52%
Usd Profit---3204515.000-30349045.750+847%-29545163.500+822%-17758362.150+454%-17062166.905+432%
Usd Revenue--319468.000142289.000+125%-+100%28457.800+1023%27102.667+1079%
Usd Total Gains Per Share---0.838-0.424-49%-1.792+114%-0.547-35%0.259-424%
 EOD+5 -3MRQTTM+12 -21YOY+20 -135Y+13 -2010Y+13 -20

4.2. Fundamental Score

Let's check the fundamental score of Aprea Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.770
Price to Book Ratio (EOD)Between0-11.118
Net Profit Margin (MRQ)Greater than0-10.031
Operating Margin (MRQ)Greater than0-11.018
Quick Ratio (MRQ)Greater than16.086
Current Ratio (MRQ)Greater than16.154
Debt to Asset Ratio (MRQ)Less than10.213
Debt to Equity Ratio (MRQ)Less than10.270
Return on Equity (MRQ)Greater than0.15-0.158
Return on Assets (MRQ)Greater than0.05-0.124
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Aprea Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5045.412
Ma 20Greater thanMa 506.811
Ma 50Greater thanMa 1006.352
Ma 100Greater thanMa 2005.263
OpenGreater thanClose6.310
Total4/5 (80.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-09-302022-12-312023-03-312023-06-302023-09-30
Total Other Income Expense Net 200-2617456229-17356-59-3



Latest Balance Sheet

Balance Sheet of 2023-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets25,766
Total Liabilities5,477
Total Stockholder Equity20,289
 As reported
Total Liabilities 5,477
Total Stockholder Equity+ 20,289
Total Assets = 25,766

Assets

Total Assets25,766
Total Current Assets25,640
Long-term Assets127
Total Current Assets
Cash And Cash Equivalents 25,354
Other Current Assets 286
Total Current Assets  (as reported)25,640
Total Current Assets  (calculated)25,640
+/-0
Long-term Assets
Property Plant Equipment 86
Long-term Assets Other 40
Long-term Assets  (as reported)127
Long-term Assets  (calculated)127
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities4,166
Long-term Liabilities1,311
Total Stockholder Equity20,289
Total Current Liabilities
Accounts payable 863
Other Current Liabilities 3,304
Total Current Liabilities  (as reported)4,166
Total Current Liabilities  (calculated)4,166
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)1,311
Long-term Liabilities  (calculated)0
+/- 1,311
Total Stockholder Equity
Common Stock4
Retained Earnings -304,640
Accumulated Other Comprehensive Income -10,636
Other Stockholders Equity 334,250
Total Stockholder Equity (as reported)20,289
Total Stockholder Equity (calculated)18,978
+/- 1,311
Other
Capital Stock4
Cash and Short Term Investments 25,354
Common Stock Shares Outstanding 3,735
Liabilities and Stockholders Equity 25,766
Net Debt -25,354
Net Invested Capital 20,289
Net Working Capital 21,474



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302014-12-312014-09-30
> Total Assets 
0
0
66,023
66,023
62,215
62,215
57,336
133,608
125,125
114,819
102,834
92,805
80,395
71,550
62,485
56,823
50,337
40,684
33,622
30,156
32,020
28,681
25,766
25,76628,68132,02030,15633,62240,68450,33756,82362,48571,55080,39592,805102,834114,819125,125133,60857,33662,21562,21566,02366,02300
   > Total Current Assets 
0
0
65,998
65,998
61,911
61,911
56,745
133,045
124,604
114,337
102,404
92,417
80,084
71,298
62,179
56,584
50,045
40,463
33,474
30,154
32,019
28,639
25,640
25,64028,63932,01930,15433,47440,46350,04556,58462,17971,29880,08492,417102,404114,337124,604133,04556,74561,91161,91165,99865,99800
       Cash And Cash Equivalents 
0
0
65,676
65,676
60,995
60,995
52,334
130,089
122,513
112,862
101,147
89,018
77,616
69,804
61,428
53,076
47,652
39,062
33,113
28,787
30,996
27,685
25,354
25,35427,68530,99628,78733,11339,06247,65253,07661,42869,80477,61689,018101,147112,862122,513130,08952,33460,99560,99565,67665,67600
       Other Current Assets 
0
0
0
322
625
292
340
2,956
2,091
1,475
1,257
3,399
2,467
1,494
751
3,508
2,393
1,401
361
1,367
1,023
954
286
2869541,0231,3673611,4012,3933,5087511,4942,4673,3991,2571,4752,0912,956340292625322000
   > Long-term Assets 
0
0
0
25
0
303
591
563
521
482
431
389
311
251
306
239
292
221
148
2
2
42
127
1274222148221292239306251311389431482521563591303025000
       Property Plant Equipment 
0
0
24
24
303
303
591
563
521
453
401
389
282
222
276
239
263
191
119
2
2
2
86
86222119191263239276222282389401453521563591303303242400
       Other Assets 
0
0
0
0
0
0
0
0
29
29
390
350
29
29
29
29
0
29
29
0
0
40
0
040002929029292929350390292900000000
> Total Liabilities 
5,911
5,962
4,868
117,459
5,878
5,878
128,132
9,364
11,772
14,698
13,811
15,410
11,249
10,598
9,070
7,316
6,748
76,462
6,997
4,512
5,538
5,262
5,477
5,4775,2625,5384,5126,99776,4626,7487,3169,07010,59811,24915,41013,81114,69811,7729,364128,1325,8785,878117,4594,8685,9625,911
   > Total Current Liabilities 
5,911
5,962
4,868
4,868
5,696
5,696
9,584
9,062
11,544
14,513
13,679
15,331
11,215
10,598
9,040
7,316
6,720
7,684
3,998
3,201
4,227
3,951
4,166
4,1663,9514,2273,2013,9987,6846,7207,3169,04010,59811,21515,33113,67914,51311,5449,0629,5845,6965,6964,8684,8685,9625,911
       Short-term Debt 
1,478
1,478
0
0
0
112
227
242
239
242
244
256
226
199
224
190
219
189
111
0
0
0
0
00001111892191902241992262562442422392422271120001,4781,478
       Short Long Term Debt 
1,478
1,478
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000001,4781,478
       Accounts payable 
4,433
4,484
1,739
1,739
2,324
2,324
3,510
2,177
3,007
5,443
4,350
4,504
3,457
2,361
2,548
1,773
1,988
3,990
1,136
843
826
1,131
863
8631,1318268431,1363,9901,9881,7732,5482,3613,4574,5044,3505,4433,0072,1773,5102,3242,3241,7391,7394,4844,433
       Other Current Liabilities 
0
0
0
3,129
0
3,260
5,847
6,643
8,299
8,828
9,084
10,571
7,532
8,038
6,267
5,353
4,513
3,505
2,752
2,358
3,401
2,820
3,304
3,3042,8203,4012,3582,7523,5054,5135,3536,2678,0387,53210,5719,0848,8288,2996,6435,8473,26003,129000
   > Long-term Liabilities 
0
0
0
112,591
0
182
118,547
303
227
186
133
79
34
0
30
1,964
28
68,777
2,999
1,311
1,311
1,311
1,311
1,3111,3111,3111,3112,99968,777281,9643003479133186227303118,5471820112,591000
> Total Stockholder Equity
-5,911
-5,962
-51,436
-51,436
-61,852
56,337
-70,796
124,244
113,354
100,120
89,023
77,395
69,146
60,952
53,415
49,507
43,589
-35,778
26,625
25,644
26,482
23,419
20,289
20,28923,41926,48225,64426,625-35,77843,58949,50753,41560,95269,14677,39589,023100,120113,354124,244-70,79656,337-61,852-51,436-51,436-5,962-5,911
   Common Stock
50
50
102
127
103
14
1
21
21
21
21
21
21
21
21
22
22
23
52
3
4
4
4
44435223222221212121212121211141031271025050
   Retained Earnings -304,640-301,435-298,176-293,796-291,354-287,330-189,071-181,134-173,379-163,927-153,676-144,007-128,615-116,296-99,929-90,528-77,456-71,206-71,206-62,468-62,468-6,197-6,146
   Capital Surplus 
0
0
0
0
0
19,998
20,347
226,285
227,220
0
0
231,418
233,241
235,104
0
0
0
0
0
0
0
0
0
000000000235,104233,241231,41800227,220226,28520,34719,99800000
   Treasury Stock00000000000000000000000
   Other Stockholders Equity 
0
0
-8,761
19,667
-10,748
138,276
13,864
226,285
227,220
228,597
229,987
231,418
233,241
235,104
237,228
240,978
243,062
193,018
325,169
328,750
333,905
334,174
334,250
334,250334,174333,905328,750325,169193,018243,062240,978237,228235,104233,241231,418229,987228,597227,220226,28513,864138,276-10,74819,667-8,76100



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue--
Gross Profit-0
 
Operating Income (+$)
Gross Profit-
Operating Expense-14,449
Operating Income-14,449-14,449
 
Operating Expense (+$)
Research Development6,113
Selling General Administrative8,905
Selling And Marketing Expenses-
Operating Expense14,44915,018
 
Net Interest Income (+$)
Interest Income-
Interest Expense--
Other Finance Cost-1,157
Net Interest Income1,157
 
Pretax Income (+$)
Operating Income-14,449
Net Interest Income1,157
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-13,286-14,455
EBIT - interestExpense = 0
-13,286
-13,286
Interest Expense-
Earnings Before Interest and Taxes (EBIT)--13,286
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax-13,286
Tax Provision--
Net Income From Continuing Ops-13,286-13,286
Net Income-13,286
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net6-1,157
 

Technical Analysis of Aprea
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Aprea. The general trend of Aprea is BULLISH with 57.1% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Aprea's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (57.1%) Bearish trend (-57.1%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Aprea Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 6.8799 < 8.8465 < 9.04.

The bearish price targets are: 5.05 > 5.03 > 4.8201.

Tweet this
Aprea Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Aprea Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 11/14.
The longshort score for the Moving Averages is 8/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Aprea Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Aprea Therapeutics Inc. The current macd is -0.14198531.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Aprea price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Aprea. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Aprea price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Aprea Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartAprea Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Aprea Therapeutics Inc. The current adx is 23.32.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Aprea shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Aprea Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Aprea Therapeutics Inc. The current sar is 6.67881349.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Aprea Therapeutics Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Aprea Therapeutics Inc. The current rsi is 45.41. The current phase is Correction in bull market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Correction in bull market: Moderate price decline, potential pause in the uptrend. Reassess the market, wait for signs of stabilization.
  • Trending up: The RSI is trending up. +1
Aprea Therapeutics Inc Daily Relative Strength Index (RSI) ChartAprea Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Aprea Therapeutics Inc. The current phase is Correction in bull market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Aprea price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Aprea Therapeutics Inc Daily Stochastic Oscillator ChartAprea Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Aprea Therapeutics Inc. The current cci is -58.63945601.

Aprea Therapeutics Inc Daily Commodity Channel Index (CCI) ChartAprea Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Aprea Therapeutics Inc. The current cmo is -14.57411885.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Aprea Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartAprea Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Aprea Therapeutics Inc. The current willr is -66.55737705.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Aprea is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Aprea Therapeutics Inc Daily Williams %R ChartAprea Therapeutics Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Aprea Therapeutics Inc.

Aprea Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Aprea Therapeutics Inc. The current atr is 0.61261274.

Aprea Therapeutics Inc Daily Average True Range (ATR) ChartAprea Therapeutics Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Aprea Therapeutics Inc. The current obv is 1,741,225.

Aprea Therapeutics Inc Daily On-Balance Volume (OBV) ChartAprea Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Aprea Therapeutics Inc. The current mfi is 5.98742463.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -2/(-2 +2).

  • MFI < 50: -1
  • MFI < 20: -1
Aprea Therapeutics Inc Daily Money Flow Index (MFI) ChartAprea Therapeutics Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Aprea Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-03DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-07SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-09MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-11-10STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-13STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-14CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-15STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-21MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-11-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-24MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-27STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-29MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-12-01STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-04MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-12-06STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-07STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-12CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-13SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-14WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-18STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-19STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-20SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-21CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-12-26MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-12-27STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-04RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-05MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-09WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-11RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-01-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-17SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-18MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-23MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-26CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-30STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-01CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-05MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-06ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-07RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-09ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-14SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-15CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-20STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-23MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-27WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-29BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-01RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-04WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-07STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-12WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-13CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-15ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-19CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-20STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Aprea Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Aprea Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5045.412
Ma 20Greater thanMa 506.811
Ma 50Greater thanMa 1006.352
Ma 100Greater thanMa 2005.263
OpenGreater thanClose6.310
Total4/5 (80.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Aprea with someone you think should read this too:
  • Are you bullish or bearish on Aprea? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Aprea? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Aprea Therapeutics Inc

I send you an email if I find something interesting about Aprea Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Aprea Therapeutics Inc.

Receive notifications about Aprea Therapeutics Inc in your mailbox!